Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birinapant - Medivir AB

Drug Profile

Birinapant - Medivir AB

Alternative Names: TL-32711

Latest Information Update: 21 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Princeton University
  • Developer Medivir AB; National Cancer Institute (USA); University of Pennsylvania
  • Class Amides; Antineoplastics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Hepatitis B; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Head and neck cancer
  • No development reported HIV infections; Legionella infections; Lymphoma; Pancreatic cancer; Tuberculosis

Most Recent Events

  • 23 Jan 2019 National Cancer Institute plans a phase I trial for Squamous Cell Carcinoma of the head and neck (Second-line therapy or greater, recurrent) in USA (NCT03809208)
  • 07 Jan 2019 Phase-I clinical trials in Head and neck cancer (Second-line therapy or greater, Recurrent, Combination therapy) in USA (IV) (NCT03803774)
  • 21 Dec 2018 Phase-II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Refractory metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02587962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top